These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 33272982)

  • 1. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial.
    Montfort A; Filleron T; Virazels M; Dufau C; Milhès J; Pagès C; Olivier P; Ayyoub M; Mounier M; Lusque A; Brayer S; Delord JP; Andrieu-Abadie N; Levade T; Colacios C; Ségui B; Meyer N
    Clin Cancer Res; 2021 Feb; 27(4):1037-1047. PubMed ID: 33272982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
    Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.
    Shoushtari AN; Friedman CF; Navid-Azarbaijani P; Postow MA; Callahan MK; Momtaz P; Panageas KS; Wolchok JD; Chapman PB
    JAMA Oncol; 2018 Jan; 4(1):98-101. PubMed ID: 28817755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
    Callahan MK; Kluger H; Postow MA; Segal NH; Lesokhin A; Atkins MB; Kirkwood JM; Krishnan S; Bhore R; Horak C; Wolchok JD; Sznol M
    J Clin Oncol; 2018 Feb; 36(4):391-398. PubMed ID: 29040030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
    Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab - study protocol.
    Janssen JC; van Dijk B; de Joode K; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; van den Eertwegh AJM; de Groot JWB; Jalving M; de Jonge MJA; Joosse A; Kapiteijn E; Kamphuis-Huismans AM; Naipal KAT; Piersma D; Rikhof B; Westgeest HM; Vreugdenhil G; Oomen-de Hoop E; Mulder EEAP; van der Veldt AAM
    BMC Cancer; 2024 May; 24(1):632. PubMed ID: 38783238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
    Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
    J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
    Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors.
    Wang LX; Quach HT; Moodabigil NV; Davis EJ; Sosman JA; Dusetzina SB; Johnson DB
    Cancer; 2020 Jan; 126(2):322-328. PubMed ID: 31580492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study.
    Namikawa K; Kiyohara Y; Takenouchi T; Uhara H; Uchi H; Yoshikawa S; Takatsuka S; Koga H; Wada N; Minami H; Hatsumichi M; Asada S; Namba Y; Yamazaki N
    Eur J Cancer; 2018 Dec; 105():114-126. PubMed ID: 30447539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
    Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
    Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
    Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
    Schadendorf D; Wolchok JD; Hodi FS; Chiarion-Sileni V; Gonzalez R; Rutkowski P; Grob JJ; Cowey CL; Lao CD; Chesney J; Robert C; Grossmann K; McDermott D; Walker D; Bhore R; Larkin J; Postow MA
    J Clin Oncol; 2017 Dec; 35(34):3807-3814. PubMed ID: 28841387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
    Sznol M; Ferrucci PF; Hogg D; Atkins MB; Wolter P; Guidoboni M; Lebbé C; Kirkwood JM; Schachter J; Daniels GA; Hassel J; Cebon J; Gerritsen W; Atkinson V; Thomas L; McCaffrey J; Power D; Walker D; Bhore R; Jiang J; Hodi FS; Wolchok JD
    J Clin Oncol; 2017 Dec; 35(34):3815-3822. PubMed ID: 28915085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
    Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
    Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
    Larkin J; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hogg D; Hill A; Márquez-Rodas I; Haanen J; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bastholt L; Rizzo JI; Balogh A; Moshyk A; Hodi FS; Wolchok JD
    N Engl J Med; 2019 Oct; 381(16):1535-1546. PubMed ID: 31562797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases.
    Di Giacomo AM; Chiarion-Sileni V; Del Vecchio M; Ferrucci PF; Guida M; Quaglino P; Guidoboni M; Marchetti P; Cutaia O; Amato G; Covre A; Camerini R; Calabrò L; Valente M; Giannarelli D; Mandalà M; Maio M
    Clin Cancer Res; 2021 Sep; 27(17):4737-4745. PubMed ID: 34112708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.